ORIC Pharmaceuticals Q1 2024 Earnings Report $8.15 -0.18 (-2.16%) (As of 11:40 AM ET) Earnings HistoryForecast ORIC Pharmaceuticals EPS ResultsActual EPS-$0.37Consensus EPS -$0.44Beat/MissBeat by +$0.07One Year Ago EPSN/AORIC Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AORIC Pharmaceuticals Announcement DetailsQuarterQ1 2024Date5/6/2024TimeN/AConference Call ResourcesPress ReleaseORIC Earnings HistoryPowered by Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> ORIC Pharmaceuticals Earnings HeadlinesAnalysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) PT at $18.29December 23 at 3:49 AM | americanbankingnews.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 25, 2024 | globenewswire.comA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading system finds high-probability option trades in less than 60 seconds a dayDecember 24, 2024 | Prosper Trading Academy (Ad)Oric Pharmaceuticals Reports Strong Financial Growth and Clinical ProgressNovember 14, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)November 13, 2024 | markets.businessinsider.comORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational UpdatesNovember 13, 2024 | markets.businessinsider.comSee More ORIC Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ORIC Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ORIC Pharmaceuticals and other key companies, straight to your email. Email Address About ORIC PharmaceuticalsORIC Pharmaceuticals (NASDAQ:ORIC), a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.View ORIC Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.